SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
SC 13E3/A	Oct 2, 2026	Oct 2, 2026	View filing
CT ORDER	Oct 2, 2026	Oct 2, 2026	View filing
4	Sep 22, 2026	Sep 22, 2026	View filing
4	Sep 22, 2026	Sep 22, 2026	View filing
4	Sep 22, 2026	Sep 22, 2026	View filing
4	Sep 22, 2026	Sep 22, 2026	View filing
425	Sep 15, 2026	Sep 15, 2026	View filing
SC 13E3	Aug 31, 2026	Aug 31, 2026	View filing
8-K	Aug 20, 2026	Aug 20, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Aug 4, 2026	Aug 4, 2026	View filing
SC 13G	Jul 29, 2026	Jul 29, 2026	View filing
SC 13D/A	Jul 21, 2026	Jul 21, 2026	View filing
425	Jul 20, 2026	Jul 20, 2026	View filing
8-K	Jul 20, 2026	Jul 20, 2026	View filing
425	Jul 20, 2026	Jul 20, 2026	View filing
425	Jul 20, 2026	Jul 20, 2026	View filing
425	Jul 20, 2026	Jul 20, 2026	View filing
425	Jul 20, 2026	Jul 20, 2026	View filing
425	Jul 20, 2026	Jul 20, 2026	View filing
8-K	Jul 20, 2026	Jul 20, 2026	View filing
4	Jul 15, 2026	Jul 15, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 26, 2026	Jun 26, 2026	View filing
4	Jun 26, 2026	Jun 26, 2026	View filing
4/A	Jun 11, 2026	Jun 11, 2026	View filing
SC 13D/A	Jun 10, 2026	Jun 10, 2026	View filing

About Personalis, Inc.

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.

Fremont, CA

260 employees

www.personalis.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Christopher Hall

View full financials